Rapid Dose Announces Closing of First Tranche of Common Share Private Placement
Rapid Dose Therapeutics Corp. (CSE: DOSE) has successfully closed the first tranche of its previously announced equity private placement financing, raising $309,000 in gross proceeds. The company issued 1,817,647 common shares at a price of $0.17 per share. This is part of a larger financing effort that allows for a maximum of $6,000,000 in gross proceeds, consisting of up to 35,294,117 common shares.
The funds will be utilized for research and development, capital expansion, debt repayment, and general working capital requirements. The issued shares are subject to a four-month hold period from the closing date, in compliance with applicable securities laws.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha completato con successo la prima tranche della sua finanziamento di collocamento privato di capitale previamente annunciata, raccogliendo $309.000 in proventi lordi. L'azienda ha emesso 1.817.647 azioni ordinarie a un prezzo di $0,17 per azione. Questo fa parte di un'iniziativa di finanziamento più ampia che consente un massimo di $6.000.000 in proventi lordi, consistendo in un massimo di 35.294.117 azioni ordinarie.
I fondi saranno utilizzati per ricerca e sviluppo, espansione del capitale, rimborso del debito e requisiti generali di capitale operativo. Le azioni emesse sono soggette a un periodo di blocco di quattro mesi dalla data di chiusura, in conformità con le leggi sui titoli applicabili.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha cerrado con éxito la primera tranche de su financiamiento de colocación privada de capital previamente anunciado, recaudando $309,000 en ingresos brutos. La compañía emitió 1,817,647 acciones ordinarias a un precio de $0.17 por acción. Esto forma parte de un esfuerzo de financiamiento más grande que permite un máximo de $6,000,000 en ingresos brutos, consistiendo en hasta 35,294,117 acciones ordinarias.
Los fondos se utilizarán para investigación y desarrollo, expansión de capital, pago de deudas y requisitos generales de capital de trabajo. Las acciones emitidas están sujetas a un período de retención de cuatro meses a partir de la fecha de cierre, en cumplimiento de las leyes de valores aplicables.
Rapid Dose Therapeutics Corp. (CSE: DOSE)는 이전에 발표된 주식 사모펀드 자금 조달의 첫 번째 트랜치를 성공적으로 마감했으며, 총 $309,000의 수익을 올렸습니다. 회사는 1,817,647주의 보통주를 주당 $0.17의 가격으로 발행했습니다. 이는 최대 $6,000,000의 총 수익을 허용하는 더 큰 자금 조달 노력의 일환으로, 최대 35,294,117주의 보통주로 구성됩니다.
이 자금은 연구 및 개발, 자본 확장, 부채 상환 및 일반 운영 자본 요구 사항에 사용될 것입니다. 발행된 주식은 종료일로부터 4개월 간의 보유 기간이 적용되며, 이는 관련 증권 법률에 따릅니다.
Rapid Dose Therapeutics Corp. (CSE: DOSE) a réussi à clôturer la première tranche de son financement de placement privé en actions annoncé précédemment, levant 309 000 $ de revenus bruts. La société a émis 1 817 647 actions ordinaires à un prix de 0,17 $ par action. Cela fait partie d'un effort de financement plus large qui permet un maximum de 6 000 000 $ de revenus bruts, composé de jusqu'à 35 294 117 actions ordinaires.
Les fonds seront utilisés pour la recherche et le développement, l'expansion du capital, le remboursement de la dette et les besoins généraux en fonds de roulement. Les actions émises sont soumises à une période de blocage de quatre mois à partir de la date de clôture, conformément aux lois sur les valeurs mobilières applicables.
Rapid Dose Therapeutics Corp. (CSE: DOSE) hat erfolgreich die erste Tranche ihrer zuvor angekündigten Kapitalerhöhung im Rahmen einer privaten Platzierung abgeschlossen und $309.000 brutto erzielt. Das Unternehmen hat 1.817.647 Stammaktien zu einem Preis von $0,17 pro Aktie ausgegeben. Dies ist Teil eines umfangreicheren Finanzierungsansatzes, der maximal $6.000.000 brutto ermöglicht, bestehend aus bis zu 35.294.117 Stammaktien.
Die Mittel werden für Forschung und Entwicklung, Kapitalerweiterung, Schuldenrückzahlung und allgemeine Betriebsmittel verwendet. Die ausgegebenen Aktien unterliegen einer viermonatigen Haltedauer ab dem Abschlussdatum gemäß den geltenden Wertpapiergesetzen.
- Successfully raised $309,000 in the first tranche of equity financing
- Potential to raise up to $6,000,000 in total gross proceeds
- Funds allocated for R&D, capital expansion, and debt repayment
- Equity dilution due to issuance of new common shares
- Only 5.15% of the maximum targeted financing amount raised in the first tranche
Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of
The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.
The Financing allowed for a maximum of
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in this news release in particular, statements regarding the size and completion of the Financing and the use of proceeds from the Financing, and in general, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results, are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217220
FAQ
How much did Rapid Dose Therapeutics (RDTCF) raise in the first tranche of its private placement?
What is the price per share for Rapid Dose Therapeutics' (RDTCF) private placement?
How many common shares did Rapid Dose Therapeutics (RDTCF) issue in the first tranche?
What is the maximum amount Rapid Dose Therapeutics (RDTCF) aims to raise through this financing?
How will Rapid Dose Therapeutics (RDTCF) use the proceeds from the private placement?
